You are here

Inhaling or having cutaneous contact with nitroglycerine and nitroglycol

Document
Last amended 
10 June 2015

Ischaemic heart disease - Inhaling or having cutaneous contact with nitroglycerine and nitroglycol Factor

This factor only applies to reasonable hypothesis cases.  In addition, it is a requirement of the SOP that the last inhalation or contact occurred not more than 14 days before the onset or worsening of ischaemic heart disease.  Therefore, for ischaemic heart disease to be related to any exposure during operational service, the onset or worsening of the heart disease would need to have occurred during, or within 2 weeks after, that service.

General information

Products containing nitroglycerine or nitroglycol include double and triple base gun propellants and gelatinous explosives such as gelignite.

Exposure to nitroglycerine or nitroglycol by Australian Defence Force personnel
 

Additional information may also be found in Physical requirements, duties, and workplace hazards of specific military occupations.

Last review for CCPS 27 April 2010.

Investigative Documents
Type Title PDF Format Word Format
Claimant Report
Inhaling or having cutaneous contact with products containing nitroglycerine or nitroglycol
CR9108.pdf
CR9108.docx
Preliminary questions [24619]

24620 there is some evidence that experiencing inhalation of or cutaneous contact with products containing nitroglycerine or nitroglycol may be a factor in the development or worsening of the condition under consideration.

26962  the veteran has established the causal connection between experiencing inhalation of, or cutaneous contact with, products containing nitroglycerine or nitroglycol and VEA service for ischaemic heart disease.

24624   the veteran has established the causal connection between experiencing inhalation of, or cutaneous contact with, products containing nitroglycerine or nitroglycol and operational service for the clinical onset of ischaemic heart disease.

or

7334     the clinical onset of the condition under consideration occurred after the end of the veteran's last period of VEA service.

7335     the condition under consideration permanently worsened.

26964   the veteran has established the causal connection between experiencing inhalation of, or cutaneous contact with, products containing nitroglycerine or nitroglycol and operational service for the clinical worsening of ischaemic heart disease.

Clinical onset and operational service [24624]

24626 the clinical onset of the condition under consideration occurred during operational service or within the 14 days following a period of operational service.

26961 the veteran has experienced inhalation of, or cutaneous contact with, products containing nitroglycerine or nitroglycol at some time.

24635 the veteran experienced inhalation of, or cutaneous contact with, products containing nitroglycerine or nitroglycol on operational service.

24627 during operational service the veteran experienced inhalation of, or cutaneous contact with, products containing nitroglycerine or nitroglycol each day for at least 20 days within a consecutive period of 30 days.

24628 during operational service the veteran experienced inhalation of, or cutaneous contact with, products containing nitroglycerine or nitroglycol each day for at least 20 days within a consecutive period of 30 days before the clinical onset of the condition under consideration, where the last exposure occurred not more than 14 days before the clinical onset.

33541 the veteran's inhalation of, or cutaneous contact with, products containing nitroglycerine or nitroglycol each day for at least 20 days within a consecutive period of 30 days before the clinical onset of the condition under consideration, on operational service, where the last exposure occurred not more than 14 days before the clinical onset, was due to the veteran's serious default, wilful act or serious breach of discipline.

Clinical worsening and operational service [26964]

26966 the clinical worsening of the condition under consideration occurred during operational service or within the 14 days following a period of operational service.

26961 the veteran has experienced inhalation of, or cutaneous contact with, products containing nitroglycerine or nitroglycol at some time.

24635 the veteran experienced inhalation of, or cutaneous contact with, products containing nitroglycerine or nitroglycol on operational service.

24627 during operational service the veteran experienced inhalation of, or cutaneous contact with, products containing nitroglycerine or nitroglycol each day for at least 20 days within a consecutive period of 30 days.

26967 during operational service, the veteran experienced inhalation of, or cutaneous contact with, products containing nitroglycerine or nitroglycol each day for at least 20 days within a consecutive period of 30 days before the clinical worsening of the condition under consideration, where the last exposure occurred not more than 14 days before the clinical worsening.

26968 the clinical onset of the condition under consideration occurred before the veteran's inhalation of, or cutaneous contact with, products containing nitroglycerine or nitroglycol on operational service made a material contribution to the requirements of the Statement of Principles for the condition under consideration.

33542 the veteran's inhalation of, or cutaneous contact with, products containing nitroglycerine or nitroglycol each day for at least 20 days within a consecutive period of 30 days before the clinical worsening of the condition under consideration, on operational service, where the last exposure occurred not more than 14 days before the clinical worsening, was due to the veteran's serious default, wilful act or serious breach of discipline.